David Steensma, Chief Medical Officer of Ajax Therapeutics, posted on X/Twitter:
“After so many years of involvement in HMA+ combination trials in MDS, it is fascinating to see combination trials of ruxolitinib+ reading out in myelofibrosis.”
Source: David Steensma/Twitter